drugset / Trial / NCT01152671

A Study of RO5024048 in Japanese and Caucasian Healthy Volunteers

NCT01152671

Phase 1 Completed 97 enrolled Hoffmann-La Roche
RandomizedParallel-groupDouble-blind

Summary

This randomized, double-blind, placebo-controlled study will assess the safety, tolerability and pharmacokinetics of RO5024048. Japanese and Caucasian healthy volunteers will be randomized to receive either single oral doses of RO5024048 or placebo. Follow-up is 7-10 days.

Timeline

Start
2010-06
Primary completion
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject mericitabine Small molecule Oral

Indications

No indication recorded.